Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMRIX vs ANAFRANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Clomipramine is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, with a higher potency for serotonin reuptake inhibition. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
Treatment of spasticity due to multiple sclerosis, spinal cord injury, or other spinal cord disorders
Obsessive-compulsive disorder (OCD),Off-label: depression, panic disorder, chronic pain, cataplexy associated with narcolepsy, premature ejaculation
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
Initial: 25 mg PO tid; increase gradually to 100-150 mg/day. Maximum: 250 mg/day. Maintenance: lowest effective dose.
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
Terminal elimination half-life of clomipramine is approximately 21-26 hours; its active metabolite, desmethylclomipramine, has a half-life of approximately 36-42 hours. Steady-state is achieved within 7-14 days.
Hepatic via deamination; primarily metabolized by monoamine oxidase B (MAO-B) to inactive metabolites.
Primarily hepatic via CYP1A2, CYP3A4, CYP2C19, and CYP2D6; active metabolite desmethylclomipramine formed via N-demethylation.
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
Renal (primarily as conjugated metabolites, ~60-70% over 72 hours); fecal (biliary excretion of ~10-20%); <2% excreted unchanged in urine.
40–45% bound to serum proteins, primarily albumin
97.6% bound primarily to alpha1-acid glycoprotein and albumin.
5–8 L/kg; suggests extensive tissue distribution, including skeletal muscle
Approximately 12-17 L/kg, indicating extensive tissue distribution.
Oral: 85–95% (extended-release formulation)
Oral bioavailability is approximately 45-55% due to first-pass metabolism. IV administration yields 100%.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min).
No specific guidelines. Use with caution in severe renal impairment (Cr Cl <30 m L/min); consider dose reduction based on tolerability.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B: initiate at 15 mg once daily; do not increase dose. Use with caution.
Child-Pugh A: no adjustment needed. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients under 12 years. For ages 12 and older, same as adult dosing.
Not recommended for children <10 years. For adolescents: initial 25 mg PO daily, increase slowly to 3 mg/kg/day or 100 mg/day maximum (whichever is lower).
Initiate at 15 mg once daily. Due to higher incidence of anticholinergic effects and falls, monitor closely; consider lower doses in frail elderly.
Initial: 10 mg PO daily; increase slowly to 30-50 mg/day. Monitor for orthostatic hypotension, sedation, and anticholinergic effects.
None
Suicidality and Antidepressant Drugs: Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior.
Abrupt discontinuation may precipitate withdrawal syndrome including hallucinations, seizures, autonomic instability.,May cause sedation, dizziness, and muscle weakness; caution with activities requiring alertness.,Use with caution in patients with impaired renal function due to reduced clearance.,May exacerbate seizures in patients with epilepsy.,Avoid concomitant use with other CNS depressants.
May increase risk of suicidal thoughts/behaviors; serotonin syndrome when used with other serotonergic drugs; lowering of seizure threshold; orthostatic hypotension; anticholinergic effects (e.g., urinary retention, blurred vision); cardiac conduction abnormalities; QT prolongation; neuroleptic malignant syndrome; angle-closure glaucoma; hyperpyrexia; withdrawal symptoms upon abrupt discontinuation; use with caution in patients with cardiovascular disease, hepatic impairment, renal impairment, history of seizures, and elderly patients.
Hypersensitivity to amrix or baclofen.,Abrupt withdrawal is contraindicated; must be tapered.,Concomitant use with MAO inhibitors is contraindicated due to risk of hypertensive crisis.
Hypersensitivity to clomipramine or other tricyclics; concurrent use or within 14 days of MAO inhibitors; recent myocardial infarction; history of seizure disorder; narrow-angle glaucoma; urinary retention; concurrent use with linezolid or methylene blue.
Avoid grapefruit and grapefruit juice during treatment as they may increase cyclobenzaprine levels. Taking AMRIX with or without food does not significantly affect absorption. Alcohol should be strictly avoided as it potentiates CNS depression.
Avoid grapefruit and grapefruit juice as they may increase clomipramine levels. Take with food to reduce gastric upset. Avoid excessive caffeine; it may increase side effects like anxiety or tremors. Limit alcohol due to additive CNS depression.
Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacking. Use only if clearly needed. First trimester: no specific teratogenic effects documented; second and third trimesters: avoid near term due to potential neonatal effects (e.g., sedation, withdrawal).
First trimester: Limited data; possible increased risk of congenital heart defects (RR ~1.3). Second/third trimester: Risk of neonatal withdrawal syndrome (jitteriness, feeding difficulties, respiratory distress) and persistent pulmonary hypertension of the newborn (PPHN) with late exposure.
Cyclobenzaprine is excreted into human milk in small amounts. M/P ratio: not established. Use with caution in nursing mothers; monitor infant for sedation, poor feeding, or hypotonia.
Anafranil (clomipramine) is excreted into breast milk. M/P ratio approximately 0.5-1.0. Relative infant dose estimated 1-2% of maternal weight-adjusted dose. Monitor infant for drowsiness, feeding difficulties, and weight loss. Generally compatible with caution.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy; however, due to potential for increased clearance, lowest effective dose should be used. Avoid use during labor and delivery due to potential neonatal depression.
Due to increased plasma volume and enhanced hepatic metabolism in pregnancy, serum levels may decrease by up to 50%. Consider dose adjustment based on clinical response and trough levels; typical increase by 25-50% may be needed in later pregnancy. Postpartum, reduce dose to prepregnancy levels over 1-2 weeks.
AMRIX (cyclobenzaprine extended-release) should not be used longer than 2-3 weeks due to lack of evidence for efficacy in muscle spasm beyond that period. It has significant anticholinergic effects; avoid in patients with glaucoma, urinary retention, or those taking MAOIs. Do not crush or chew capsules; administer once daily at same time. Onset of action is delayed compared to immediate-release cyclobenzaprine.
Anafranil (clomipramine) is a tricyclic antidepressant (TCA) primarily used for obsessive-compulsive disorder (OCD). Monitor for QT prolongation, especially in patients with cardiac risk factors or on other QT-prolonging drugs. Due to anticholinergic effects, use cautiously in elderly, those with BPH, or narrow-angle glaucoma. Start low and titrate slowly to minimize side effects. Therapeutic response may take 2-4 weeks. Do not discontinue abruptly due to withdrawal symptoms.
Take AMRIX exactly once daily at the same time each day; do not crush, chew, or open the capsule.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase the risk of severe drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how AMRIX affects you; it may cause drowsiness, dizziness, or blurred vision.,Contact your healthcare provider if you experience symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness, nausea, diarrhea).,Do not use AMRIX for longer than 2-3 weeks unless specifically directed by your doctor; prolonged use is not recommended.,Inform your doctor if you have a history of urinary retention, glaucoma, thyroid disorders, heart problems, or liver disease.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double the dose.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,It may take several weeks to feel the full benefit; do not stop suddenly.,Avoid alcohol and other CNS depressants.,Report any suicidal thoughts, worsening depression, or mood changes immediately.,May cause drowsiness, dizziness, or blurred vision; avoid driving until you know how it affects you.,Dry mouth, constipation, and urinary retention are common; increase fluid intake and dietary fiber.,Use sun protection; this medication can increase sensitivity to sunlight.,Do not take with MAO inhibitors (e.g., linezolid, methylene blue) or within 14 days of stopping them.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMRIX vs ANAFRANIL, answered by our medical review team.
AMRIX is a Muscle Relaxant that works by Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.. ANAFRANIL is a Tricyclic Antidepressant that works by Clomipramine is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, with a higher potency for serotonin reuptake inhibition. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMRIX and ANAFRANIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMRIX is: 15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.. The standard adult dose of ANAFRANIL is: Initial: 25 mg PO tid; increase gradually to 100-150 mg/day. Maximum: 250 mg/day. Maintenance: lowest effective dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMRIX and ANAFRANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMRIX is classified as Category C. Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacki. ANAFRANIL is classified as Category C. First trimester: Limited data; possible increased risk of congenital heart defects (RR ~1.3). Second/third trimester: Risk of neonatal withdrawal syndrome (jitteriness, feeding dif. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.